177329-70-3Relevant articles and documents
Enantioselective synthesis of natural combretastatin
Ramacciotti, Alessio,Fiaschi, Rita,Napolitano, Elio
, p. 1101 - 1104 (1996)
In a process which appears to be general for the enantioselective synthesis of oxysubstituted 1,2-diarylethanols, a 4-methoxy-3-silyloxyphenyllithium, obtained by bromine-lithium exchange from the corresponding aryl bromide and t-butyllithium, added selectively at the b-carbon of (S)-2,3,4-trimethoxyphenyloxirane, elaborated from the corresponding styrene via Sharpless asymmetric dihydroxylation, to afford an adduct from which natural (-)-combretastatin was obtained by desilylation.
Synthesis and biological evaluation of 2-Indolyloxazolines as a new class of tubulin polymerization inhibitors. Discovery of A-289099 as an orally active antitumor agent
Li, Qun,Woods, Keith W.,Claiborne, Akiyo,Gwaltney, Ii, Stephen L.,Barr, Kenneth J.,Liu, Gang,Gehrke, Laura,Credo,Hui, Yu Hua,Lee, Jang,Warner, Robert B.,Kovar, Peter,Nukkala, Michael A.,Zielinski, Nicolette A.,Tahir, Stephen K.,Fitzgerald, Michael,Kim, Ki H.,Marsh, Kennan,Frost, David,Ng, Shi-Chung,Rosenberg, Saul,Sham, Hing L.
, p. 465 - 469 (2007/10/03)
A series of indole containing oxazolines has been discovered as a result of structural modifications of the lead compound A-105972. The compounds exert their anticancer activity through inhibition of tubulin polymerization by binding at the colchicine site. A-289099 was identified as an orally active antimitotic agent active against various cancer cell lines including those that express the MDR phenotype. The anticancer activity, pharmacokinetics, and an efficient and enantioselective synthesis of A-289099 are described.
